Mutations in LARS2, Encoding Mitochondrial Leucyl-tRNA Synthetase, Lead to Premature Ovarian Failure and Hearing Loss in Perrault Syndrome  by Pierce, Sarah B. et al.
REPORT
Mutations in LARS2, Encoding Mitochondrial
Leucyl-tRNA Synthetase, Lead to Premature
Ovarian Failure and Hearing Loss in Perrault Syndrome
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The genetic causes of premature ovarian failure (POF) are highly heterogeneous, and causative mutations have been identified in more
than ten genes so far. In two families affected by POF accompanied by hearing loss (together, these symptoms compose Perrault
syndrome), exome sequencing revealed mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase: homozygous
c.1565C>A (p.Thr522Asn) in a consanguineous Palestinian family and compound heterozygous c.1077delT and c.1886C>T
(p.Thr629Met) in a nonconsanguineous Slovenian family. LARS2 c.1077delT leads to a frameshift at codon 360 of the 901 residue
protein. LARS2 p.Thr522Asn occurs in the LARS2 catalytic domain at a site conserved from bacteria through mammals. LARS2
p.Thr629Met occurs in the LARS2 leucine-specific domain, which is adjacent to a catalytic loop critical in all species but for which
primary sequence is not well conserved. A recently developed method of detecting remote homologies revealed threonine at this site
in consensus sequences derived from multiple-species alignments seeded by human and E. coli residues at this region. Yeast comple-
mentation indicated that LARS2 c.1077delT is nonfunctional and that LARS2 p.Thr522Asn is partially functional. LARS2 p.Thr629Met
was functional in this assay but might be insufficient as a heterozygote with the fully nonfunctional LARS2 c.1077delT allele. A known
C. elegans strain with the protein-truncating alteration LARS-2 p.Trp247Ter was confirmed to be sterile. AfterHARS2, LARS2 is the second
gene encoding mitochondrial tRNA synthetase to be found to harbor mutations leading to Perrault syndrome, further supporting a
critical role for mitochondria in the maintenance of ovarian function and hearing.Premature ovarian failure (POF) is a major cause of infer-
tility in young women and is characterized by primary or
secondary amenorrhea and elevated levels of gonadotro-
pins long before the natural age of menopause. Severe
cases can involve ovarian dysgenesis. Nongenetic causes
of POF include autoimmune disorders, viral infection, radi-
ation, or chemotherapy. Genetic causes are highly hetero-
geneous and include both isolated (nonsyndromic) POF
and syndromic forms. Mutations that cause POF have so
far been identified in more than ten genes,1–12 but most
cases are still unresolved. Perrault syndrome (MIM
233400) is characterized by POF in females and progressive
hearing loss in both females and males. Mutations in
HSD17B4 (encoding 17-beta hydroxysteroid dehydroge-
nase 4; MIM 601860), HARS2 (encoding mitochondrial
histidyl-tRNA synthetase; MIM 600783), and CLPP (encod-
ing mitochondrial ATP-dependent chambered protease;
MIM 601119) are responsible for POF in the context of Per-
rault syndrome.9,10,12 Similarly to other cases of POF, the
majority of cases of Perrault syndrome remain unresolved.
Gene discovery for POF is challenging for a number of
reasons: its causes are extremely heterogeneous, infertility
limits the size of informative families, and the genes that
harbor causal mutations include tRNA-synthetase-encod-
ing genes, among the oldest in evolution. Such extreme
antiquity can lead to conserved protein architecture that
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of missense mutations even more difficult than usual. In
an effort to address this problem, we augmented func-
tional analysis by applying a recently developed protein-
sequence-alignment method that generates consensus
profiles from deep evolutionary roots.13,14
Genomic DNA samples from unrelated probands with
POF and hearing loss and from their unaffected parents
were evaluated in our laboratory by exome sequencing ac-
cording to previously published methods.15 The study was
approved by the human subjects committees of the institu-
tional review boards of Shaare Zedek Medical Center (with
approval from the Israel National Ethics Committee),
Ljubljana University Medical Center, and the University
of Washington. The present analysis focuses on two fami-
lies affected by candidate mutations in the same gene
(Figure 1). Family 1 is consanguineous and of Palestinian
ancestry. At 17 years old, the proband presented with
primary amenorrhea and postmenopausal levels of
follicle-stimulating hormone (FSH; 76.9 IU/l) and luteiniz-
ing hormone (LH; 30.3 IU/l). Her uterus was prepubertal in
size, and her ovaries were not visualized on abdominal
ultrasound. The family 1 proband and her two brothers
were diagnosed with sensorineural hearing loss at 3–5
years of age. The brothers’ hearing loss is severe at lower
frequencies and less severe at higher frequencies, resulting
in unusual upsloping audiograms. The profile of hearinggton, Seattle WA 98195, USA; 2Department of Genome Sciences, University
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Figure 1. LARS2 Mutations in Families Affected by POF and Hearing Loss
Family 1 is a consanguineous family of Palestinian ancestry. Daughter II-2 has POF, and all three children have sensorineural hearing
loss. Pure-tone audiometry measurements demonstrate hearing loss in II-1 (brown line), II-2 (dashed red line [age 8 years] and solid
red line [age 17 years]), and II-3 (orange line). Abbreviations are as follows: R, right ear; and L, left ear. The parents are heterozygous
and all three children are homozygous for LARS2 c.1565C>A (p.Thr522Asn). Family 2 is a nonconsanguineous family of Slovenian
ancestry. Daughter II-1 has POF and severe hearing loss. She is compound heterozygous for paternal allele LARS2 c.1077delT
(p.Ile360PhefsTer15) and maternal allele LARS2 c.1886C>T (p.Thr629Met). Mutations validated by Sanger sequencing were first iden-
tified by whole-exome sequencing.loss in the proband is unique in our experience with Per-
rault-syndrome-affected families. When she was 8 years
old, hearing loss in her right ear was mild to moderate in
mid frequencies and was mild in her left ear. When she
was 17 years old, hearing loss in her right ear was severe
at lower frequencies and less severe at higher frequencies,
resulting in an upsloping audiogram, whereas hearing
loss remained mild in her left ear. She does not use
a hearing aid. Family 2 is nonconsanguineous and of Slove-
nian ancestry. The proband, an only child, presented with
POF and severe hearing loss. She had apparently normal
menarche at age 13 years and regular menses until age
18 years, but she had no cycles between ages 19 and 30
years, her present age. Her FSH levels at age 30 years were
high (101 IU/l). Both probands had 46XX karyotypes,
normal neurological function, and normal intelligence.
In both families, family structure is consistent with auto-
somal-recessive inheritance. In family 2, family structure
is also consistent with X-linked recessive inheritance or
a dominant de novo mutation.
Exome sequencing was carried out on paired-end
libraries constructed from genomic DNA extracted from
blood and sonicated to approximately 200 bp.15 AfterThe Amquality control, the libraries were hybridized to bio-
tinylated DNA oligonucleotide baits from the SeqCap EZ
Human Exome Library v.2.0 (Roche NimbleGen), purified
by streptavidin-bound magnetic beads, amplified, and
sequenced on a HiSeq 2000 instrument (Illumina). The
exome design covers 44 Mb of the human genome, corre-
sponding to the exons and flanking intronic regions of
~300,000 coding exons, 700 miRNAs from miRBase v.14,
and 300 noncoding RNAs. Four barcoded samples were
multiplexed per lane, generating median coverage of
120-fold; 93% of targeted reads had >10-fold coverage.
DNA variants were classified by predicted function:
nonsense mutations, frameshift mutations, variants
within 1 bp of a splice site, and putatively damaging
missense variants (defined as predicted to be damaging
by PolyPhen-2 and/or SIFT online tools).
Given that family 1 is consanguineous, we filtered vari-
ants of this family’s proband to identify homozygous
damaging mutations. Only one mutation fulfilled this
criterion: c.1565C>A (p.Thr522Asn) (RefSeq accession
number NM_015340.3) at chr3: 45,537,808C>A (hg19)
in LARS2 (MIM 604544), encoding mitochondrial leucyl-
tRNA synthetase. The variant is predicted to be damagingerican Journal of Human Genetics 92, 614–620, April 4, 2013 615
A B
C D E
Figure 2. Domain Architecture and Conservation of LARS2 and Structural Analysis of the LARS2 E. coli Ortholog
(A) The domain architecture of LARS2 includes the catalytic domain, the editing domain, the leucine-specific (LS) domain, the anti-
codon-recognition domain, and the C-terminal (C-ter) domain. HIGH and KMSKS are catalytically important motifs.
(B) Protein sequence alignments of LARS2 orthologs show the regions surrounding altered residues p.Thr522 and p.Thr629 (indicated
in red).
(C) Structure of E. coli LeuRS-tRNALeu in the aminoacylation conformation (Protein Data Bank [PDB] 4AQ7). The tRNA backbone is
orange, and the bases are shown as blue and green sticks. LeuRS is gray, the leucine-specific domain is blue, and the KMSKS catalytic
loop is red. LeuRS p.Thr492 (analogous to human LARS2 p.Thr522) is in green at the intersection point indicated by the two arrows.
LeuRS p.Ala508 (analogous to human LARS2 p.Thr629) is indicated by spheres.
(D) A close view of LeuRS p.Thr492 shows that it is in very close proximity to the tRNA 30 end, to which leucine will be covalently
attached. Substitution at this position might shift the position of the tRNA and reduce aminoacylation efficiency.
(E) A close view shows that the KMSKS loop is in close proximity to the tRNA 30 end and adjacent to the leucine-specific domain. Substi-
tution at the position of LeuRS p.Ala508 with a nonpolar methionine could disrupt the structure and/or position of the leucine-specific
domain and thus shift the position of the KMSKS loop and reduce catalytic efficiency.by PolyPhen-2 (HumDiv score 1.000, HumVar score 1.000)
and SIFT (p ¼ 0.00). The variant lies in a 44 Mb region of
homozygosity, the largest homozygous region in the
proband’s genome, at 3p25.1–p21.1 between approxi-
mately 9.7 Mb and 53.7 Mb. PCR amplification and Sanger
sequencing indicated that the proband and both her
affected brothers are homozygous and their parents are
heterozygous for the variant (Figure 1). We filtered variants
of the proband of family 2 to identify homozygous,
compound heterozygous, or de novo damagingmutations.
No potentially damaging homozygous or de novo muta-
tions were detected. The proband was compound hetero-
zygous for one pair of variants both predicted to be
damaging: LARS2 c.1077delT (p.Ile360PhefsTer15)
(at chr3: 45,527,241) from her father and LARS2
c.1886C>T (p.Thr629Met) (at chr3: 45,557,610) from her
mother. LARS2 p.Thr629Met is predicted to be damaging
by PolyPhen-2 HumDiv (score 0.999) and SIFT (p ¼ 0.00)
and to be possibly damaging by PolyPhen-2 HumVar (score
0.791). None of the three LARS2 mutations were found
in 239 Palestinian controls, in 362 Slovenian controls, or
in 6,500 controls of European American or African Amer-
ican ancestries with variants released on the National
Heart, Lung, and Blood Institute (NHLBI) Exome Variant
Server.616 The American Journal of Human Genetics 92, 614–620, April 4, 2LARS2 encodes a 903 aa mitochondrial leucyl-tRNA
synthetase (Figure 2A).16 Aminoacyl-tRNA synthetases
are evolutionarily conserved enzymes that attach specific
amino acids to the 30 ends of their cognate tRNAs.17
Aminoacyl-tRNA-synthetase activity is required in the
cytoplasm and in mitochondria for the translation of nu-
clearly and mitochondrially encoded genes, respectively.
In mammals, most cytoplasmic and mitochondrial tRNA
synthetases are encoded by different genes. LARS2
c.1077delT in family 2 is predicted to yield a 373 aa trun-
cated protein with 14 novel amino acids at the C terminus.
Parts of the catalytic and editing domains, the leucine-
specific domain, and the anticodon-binding domain
would be deleted, and it is thus unlikely that a functional
protein would be produced. In family 1, the site of the
mutant residue, LARS2 p.Thr522, is highly conserved
among prokaryotic and eukaryotic species (Figure 2B). In
contrast, in family 2, the mutant residue, LARS2
p.Thr629, is at a site conserved in mammals but is poorly
conserved in more distantly related species.
The three-dimensional structures of the LARS2 E. coli or-
tholog, LeuRS, reveal possible consequences of the
missense mutations in the human families. Two structures
of the E. coli enzyme were informative: LeuRS in the ami-
noacylation conformation in complex with the 30 end of013
Figure 3. Consensus Sequences of LARS2 Leucine-Specific Domains from Alignments to Human and E. coli Sequences
Despite the dissimilarity in the sequences of human LARS2 and E. coli LeuRS leucine-specific domains, the consensus sequences for align-
ments to the human (upper) and E. coli (lower) leucine-specific domains are identical in the boxed region surrounding human LARS2
p.Thr629 (indicated by asterisk). Alignments were generated with the HHblits algorithm and displayed with WebLogo. Human and
E. coli query sequences are shown below each respective logo. Dots below indicate positions of identity between human and E. coli
sequences.tRNALeu(UAA) and a nonhydrolyzable analog of the leucyl-
adenylate (Protein Data Bank [PDB] 4AQ7) (Figure 2C); and
LeuRS in the editing conformation in complex with the 30
end of tRNALeu(UAA) (PDB 4ARC).18 In family 1, LARS2
p.Thr522 (equivalent to LeuRS p.Thr492), is located in
the highly conserved catalytic domain (Figure 2D). The
residue sits at the N-terminal end of an a-helix that forms
part of a pocket into which the 30 end of the tRNA strand
binds, and the hydroxyl group of the threonine side chain
points directly at the terminal phosphate group of the
tRNA strand. A substitution at this position could change
the position of the 30 end of the tRNA, causing a reduction
in aminoacylation efficiency. In family 2, the mutant
missense residue, LARS2 p.Thr629 (equivalent to LeuRS
p.Ala508), occurs near the C-terminal end of the poorly
conserved leucine-specific domain, just N-terminal to the
catalytically important and highly conserved KMSKS
loop (Figure 2E).19 In E. coli LeuRS, the KMSKS loop moves
as an integral part of the leucine-specific domain during
the aminoacylation and proofreading catalytic cycle,18
suggesting that the structure of the leucine-specific
domain is important, despite lack of conservation of the
primary sequence.
The conserved position of the leucine-specific domain in
eukaryotic mitochondrial and bacterial leucyl-tRNA
synthetases suggests possible underlying homology andThe Amfunctional conservation. To search for homology, we
applied amethod that uses iterative comparisons of hidden
Markov models to detect remote homology and to build
alignments of highly diverse sequences.13,14 As queries,
we used 49 residue and 59 residue sequences, including
the leucine-specific domains of human LARS2 and E. coli
LeuRS, respectively. The two domains are bounded by
conserved residues QG at the N-terminal end and KMSKS
at the C-terminal end. Each query sequence was aligned
to all possible sequences from bacterial, fungal, and protist
kingdoms for which any similarity could be detected by the
HHblits algorithm (Figure S1, available online). Each set of
alignments then yielded a consensus sequence bounded by
QG and KMSKS (Figure 3). Despite the fact that human and
E. coli sequences differ throughout this domain, the
consensus sequences generated by the two deep align-
ments are identical—KATGEPVV—at the region immedi-
ately surrounding LARS2 p.Thr629. Furthermore, methio-
nine is never seen in the position of p.Thr629 in any
species (Figure S1). The shared consensus sequences at the
region surrounding p.Thr629 suggest that there is indeed
underlying homology among species in this region of the
protein, that there is likely to be functional and possibly
structural conservation, and that threonine at this site is
conserved. The consensus region forms a highly hydro-
philic and surface-exposed loop attached to a b stranderican Journal of Human Genetics 92, 614–620, April 4, 2013 617
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Figure 4. Analysis of Mitochondrial-Leucyl-tRNA-Synthetase
Alterations in Yeast and C. elegans
(A) Yeast strain ade2 nam2D::KAN was transformed with inte-
grating vectors expressing yeast wild-type mitochondrial leucyl-
tRNA synthetase NAM2, negative control EGFP, wild-type
LARS2, and each of the three LARS2 alterations. Cells were serially
diluted 5-fold, spotted on complete media containing 2% glucose,
and incubated for 2 days at 30C. Red color indicates complemen-
tation of the nam2D::KAN mutation by the integrated allele.
(B and C) Adult C. elegans (of the strain lars-2(mg312);unc-
29(e1072)) homozygous for the protein-truncating alteration
LARS-2 p.Trp247Ter (C) are smaller and have smaller gonads (out-
lined in red) than do control unc-29(e1072) animals with wild-type
LARS-2 function (B). The absence of oocytes in the lars-2 mutant
strain indicates that germline development is arrested.that leads directly to the KMSKS catalytic loop. Substitution
of the small threonine side chain with a longer, more
aliphatic methionine side chain could affect the loop’s
ability to take on an exposed position in the structure.
We investigated the functional effects of the LARS2
mutations in families 1 and 2 by using a yeast complemen-
tation assay. We determined the ability of wild-type LARS2
and all LARS2 mutant alleles to complement the618 The American Journal of Human Genetics 92, 614–620, April 4, 2mitochondrial dysfunction caused by deletion of the
Saccharomyces cerevisiae LARS2 ortholog, NAM2. We gener-
ated a NAM2 deletion strain (nam2D::KAN), which also
carried a mutation in the adenine biosynthesis gene
ADE2. S. cerevisiae ade2 mutant cells produce a red
pigment, but only in the presence of functional mitochon-
dria.20 Cells of the ade2 nam2D::KAN strain, expressing
EGFP as a negative control, are thus white (Figure 4A).
Expression of wild-type human LARS2 or yeast NAM2
restored production of red pigment, indicating rescue of
mitochondrial function. LARS2 c.1077delT did not rescue
pigment production. Production of red pigment was
partially rescued by LARS2 p.Thr522Asn and fully rescued
by LARS2 p.Thr629Met. These results indicate that LARS2
c.1077delT is nonfunctional and that the activity of
LARS2 p.Thr522Asn is reduced relative to wild-type
LARS2. In contrast, when expressed as the sole source of
mitochondrial-leucyl-tRNA-synthetase activity, as in this
assay, LARS2 p.Thr629Met provided enough activity to
support wild-type production of red pigment.We speculate
that in the proband of family 2, the compound heterozy-
gous combination of LARS2 p.Thr629Met and LARS2
c.1077delT would yield reduced total LARS2 activity and
would thus lead to inadequate mitochondrial function in
the ovary and inner ear.
To investigate the effects of reduced activity of mito-
chondrial leucyl-tRNA synthetase on a multicellular
organism, we examined a C. elegans strain with alteration
LARS-2 p.Trp247Ter, which truncates mitochondrial
leucyl-tRNA synthetase.21 This strain, lars-2(mg312);unc-
29(e1072), had been described as small, slow growing,
sterile, and unable to produce differentiated germ cells.
We confirmed that worms homozygous for the lars-2
mutation were completely sterile—compared to the wild-
type controls (n > 30), which produced 200–250 progeny
per animal, they produced no progeny at all. Germ cell
development was arrested such that oocytes were never
observed (Figures 4B and 4C).
It is a clinical challenge to identify Perrault syndrome,
and hence ovarian failure, among prepubertal girls who
present with hearing loss. This challenge is particularly
marked given the variability of hearing loss among affected
children in families afflicted with Perrault syndrome.10,12
In the families reported here and in some affected persons
in the family harboring HARS2 mutations, audiograms
have a distinctive upward-sloping shape. Such audiograms
offer clues to a possible Perrault phenotype in affected
girls. More generally, families affected by recessively in-
herited, genetically unexplained hearing loss, detected
only in prepubertal girls or in boys, might represent new
cases of Perrault syndrome.
The identification of two Perrault-syndrome-affected
families harboring different LARS2 mutations, evolu-
tionary evidence, and model-organism results together
provide strong evidence that mutations in LARS2 cause
POF and hearing loss in these families. The 19 mitochon-
drial tRNA synthetases perform analogous roles in013
translating the 13 proteins encoded by the mitochondrial
genome. Nonetheless, mutations in genes encoding these
mitochondrial tRNA synthetases and their cognate tRNAs
result in disease phenotypes that are highly variable
among genes and, for many of the mitochondrial tRNAs,
among alleles of the same gene.17,22–27 Mutations in the
genes encoding eight mitochondrial tRNA synthetases
other than LARS2 and HARS2 cause various multisystemic
disorders involving nervous-system dysfunction, cardio-
myopathy, exercise intolerance, anemia, and kidney
failure.17,22–26 The mechanisms for such phenotypic diver-
sity are not clear. Cells and tissues might vary in vulnera-
bility to the effects of loss of function of specific tRNA
synthetases as a result of cell-type-specific variation in
gene expression or in the availability of cofactors required
for optimal enzyme activity. In addition, the extreme
genetic and allelic heterogeneity might indicate that the
components of the mitochondrial translation machinery
engage in complex interactions that are not revealed by
their canonical activities. For example, in addition to
its tRNA-synthetase activity, mitochondrial leucyl-tRNA
synthetase in yeast is involved in the splicing of transcripts
for mitochondrially encoded proteins.28
The identification of mutations in a fourth gene as
responsible for Perrault syndrome underscores the genetic
heterogeneity of this phenotype. In our small series of 15
families affected by clinically defined Perrault syndrome,
four families’ phenotypes are explained by mutations is
HARS2, HSD17B4, and LARS2, seven families have wild-
type sequences of these genes and CLPP, and four families
are presently being evaluated. Mutations in additional
genes associated with Perrault syndrome remain to be
discovered.
In mouse models, genetic changes that cause perturba-
tions in mitochondrial protein translation have been
shown to lead to hearing loss as a result of tissue-specific
apoptosis.29,30 Given the role of apoptosis in ovarian
development,31 accelerated or inappropriately timed
apoptosis might explain both cardinal features of Perrault
syndrome. The observation that mutations in a second
gene encoding a mitochondrial tRNA synthetase lead to
this phenotype suggests that mutations in genes involved
in mitochondrial tRNA processing are candidates for yet
unresolved cases and further supports a role for mitochon-
dria in the maintenance of both ovarian function and
hearing.Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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